Lipella Pharmaceuticals Inc.

NasdaqCM LIPO

Lipella Pharmaceuticals Inc. Inventory for the quarter ending September 30, 2024: USD 0.00

Lipella Pharmaceuticals Inc. Inventory is USD 0.00 for the quarter ending September 30, 2024, a 100.00% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.
  • Lipella Pharmaceuticals Inc. Inventory for the quarter ending September 30, 2023 was USD -261.01 M, a 0.00% change year over year.
  • Lipella Pharmaceuticals Inc. Inventory for the quarter ending September 30, 2022 was USD 0.00.
Key data
Date Inventory Goodwill Total Assets Current Liabilities
Market news
Loading...
NasdaqCM: LIPO

Lipella Pharmaceuticals Inc.

CEO Dr. Jonathan Kaufman M.B.A., Ph.D.
IPO Date Dec. 19, 2022
Location United States
Headquarters 7800 Susquehanna St.
Employees 5
Sector Health Care
Industries
Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Similar companies

MNPR

Monopar Therapeutics Inc.

USD 24.98

-2.76%

CELC

Celcuity Inc.

USD 10.53

-2.95%

ACRV

Acrivon Therapeutics, Inc. Common Stock

USD 5.56

0.91%

ICCC

ImmuCell Corporation

USD 5.18

-2.81%

ELVN

Enliven Therapeutics, Inc.

USD 20.46

-7.29%

FENC

Fennec Pharmaceuticals Inc.

USD 5.64

-3.09%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

SNTI

Senti Biosciences, Inc.

USD 3.81

0.53%

INBX

Inhibrx Biosciences, Inc.

USD 12.74

-6.60%

StockViz Staff

January 15, 2025

Any question? Send us an email